Cargando…

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conteduca, Vincenza, Jayaram, Anuradha, Romero-Laorden, Nuria, Wetterskog, Daniel, Salvi, Samanta, Gurioli, Giorgia, Scarpi, Emanuela, Castro, Elena, Marin-Aguilera, Mercedes, Lolli, Cristian, Schepisi, Giuseppe, Maugeri, Antonio, Wingate, Anna, Farolfi, Alberto, Casadio, Valentina, Medina, Ana, Puente, Javier, Vidal, Mª José Méndez, Morales-Barrera, Rafael, Villa-Guzmán, Jose C., Hernando, Susana, Rodriguez-Vida, Alejo, González-del-Alba, Aránzazu, Mellado, Begoña, Gonzalez-Billalabeitia, Enrique, Olmos, David, Attard, Gerhardt, De Giorgi, Ugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377278/ https://www.ncbi.nlm.nih.gov/pubmed/30773204 http://dx.doi.org/10.1016/j.eururo.2018.09.049

Ejemplares similares

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
por: González-Billalabeitia, Enrique, et al.
Publicado: (2018)

Vitamin D status among long-term survivors of testicular cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2016)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer
por: Conteduca, V., et al.
Publicado: (2017)

Genome-wide plasma DNA methylation features of metastatic prostate cancer
por: Wu, Anjui, et al.
Publicado: (2020)

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
por: Brighi, Nicole, et al.
Publicado: (2019)

Cell-free DNA as a diagnostic marker for cancer: current insights
por: Salvi, Samanta, et al.
Publicado: (2016)

Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Identification of single nucleotide variants using position-specific error estimation in deep sequencing data
por: Kleftogiannis, Dimitrios, et al.
Publicado: (2019)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
por: Conteduca, V., et al.
Publicado: (2017)

Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel
por: Gurioli, Giorgia, et al.
Publicado: (2022)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Plasma Androgen Receptor in Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
por: Schepisi, Giuseppe, et al.
Publicado: (2021)

Psychosocial Issues in Long-Term Survivors of Testicular Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges
por: Trujillo, Blanca, et al.
Publicado: (2022)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer
por: Cursano, M. C., et al.
Publicado: (2022)

Copy Number Analysis of 24 Oncogenes: MDM4 Identified as a Putative Marker for Low Recurrence Risk in Non Muscle Invasive Bladder Cancer
por: Salvi, Samanta, et al.
Publicado: (2014)

Immunotherapy for Prostate Cancer: Where We Are Headed
por: Schepisi, Giuseppe, et al.
Publicado: (2017)

GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications
por: Martignano, Filippo, et al.
Publicado: (2016)

Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
por: Jiménez, Natalia, et al.
Publicado: (2022)

Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients
por: Salvi, Samanta, et al.
Publicado: (2015)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
por: Lolli, Cristian, et al.
Publicado: (2016)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2023)

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay
por: Orlando, Francesco, et al.
Publicado: (2022)

Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review
por: Schepisi, Giuseppe, et al.
Publicado: (2021)

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
por: Salvi, S, et al.
Publicado: (2015)

Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach
por: Gurioli, Giorgia, et al.
Publicado: (2016)

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
por: Conteduca, Vincenza, et al.
Publicado: (2020)

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide
por: Fernandez‐Perez, María P., et al.
Publicado: (2022)

Copy number architectures define treatment-mediated selection of lethal prostate cancer clones
por: Hasan, A. M. Mahedi, et al.
Publicado: (2023)

Detection and Investigation of Extracellular Vesicles in Serum and Urine Supernatant of Prostate Cancer Patients
por: Salvi, Samanta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4kni6g4sdlgd1k8qh7jt578hc8